Codes of ethics cause problems for overseas operations
Corporate codes of ethics can have reverse effects and mask anomalies or social evils in operations outsourced to low-wage countries...
List view / Grid view
Corporate codes of ethics can have reverse effects and mask anomalies or social evils in operations outsourced to low-wage countries...
Digital risk calculator highlights cyber attacks and highly sensitive or valuable data as major risks for life sciences businesses
Veeva's Rik Van Mol explains how streamlining the clinical process will not only improve the speed but also the quality of the data...
This paper provides commentary on efforts for analytical data standardization and a vision of the broader considerations and requirements that such an undertaking should include...
Optimising analysis in the laboratory with modern instruments and high-performance software...
CAMO Software announced the release of Batch Modeling, a new add-on to their all-in-one Multivariate Data Analysis (MVA) and process monitoring software suite Unscrambler® X...
In this supplement, we've brought together a collection of interesting posters from leading companies in order to celebrate cutting-edge research in the pharmaceutical industry and to share with our readers some of the varied work being carried out by their colleagues...
Just under a quarter (22%) of life science companies already using or experimenting with blockchain, but industry collaboration over security and storage standards is needed…
The Global Access to Healthcare Index measures how healthcare systems across 60 countries are working to solve the most pressing healthcare needs...
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
A new report released by the UK BioIndustry Association (BIA) shows that the UK maintained its strong leadership position in European biotech funding last year and has the strongest pipeline in Europe for future drug development.
Health leaders announced the launch of the Alliance for Transparent & Affordable Prescriptions (ATAP), a coalition of provider and patient groups concerned about the practices of pharmacy benefit managers (PBMs) driving up drug costs.
In a study of 10 high-income countries with universal health care, costs for prescription drugs in 6 of the largest categories varied by more than 600%.
Diagnostic tests can help identify disease and disease probability in patients, leading to earlier treatment, but what’s the real cost?
Biotech and pharmaceutical firms hold vast amounts of valuable data and information making them prime targets for cyber-attacks – so how are they protecting themselves?